Literature DB >> 6869410

Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials.

A H Mackenzie.   

Abstract

No eye disease was detected in over 900 rheumatoid arthritis patients treated with less than 4.0 mg/kg per day of chloroquine or less than 6.5 mg/kg per day of hydroxychloroquine for a mean of about seven years. I therefore consider these dosage rates safe, since they are below the threshold of retinal toxicity. This is based on more than 6,000 patient-years of drug exposure. That dosage threshold for retinopathy appears to be 5.1 mg/kg per day for chloroquine and 7.8 mg/kg per day for hydroxychloroquine according to my studies with these compounds. The daily dosage rate, rather than total drug accumulation, seems to determine the development of eye disease. To prevent overdosage, dosing should be calculated not on the actual weight of the patient but on ideal (lean) body weight. Furthermore, the patient's renal and liver function should also be taken into account to avoid overdosage. Since exposure to light amplifies the risk of retinopathy in patients treated with antimalarials, dark sunglasses are recommended for patients spending much time in sunlight.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6869410     DOI: 10.1016/0002-9343(83)91269-x

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  56 in total

1.  Exfoliative cutaneous lupus erythematosus in German shorthaired pointer dogs: disease development, progression and evaluation of three immunomodulatory drugs (ciclosporin, hydroxychloroquine, and adalimumab) in a controlled environment.

Authors:  Elizabeth A Mauldin; Daniel O Morris; Dorothy C Brown; Margret L Casal
Journal:  Vet Dermatol       Date:  2010-04-01       Impact factor: 1.589

2.  Long-term effectiveness of antimalarial drugs in rheumatic diseases.

Authors:  J A Aviña-Zubieta; G Galindo-Rodriguez; S Newman; M E Suarez-Almazor; A S Russell
Journal:  Ann Rheum Dis       Date:  1998-10       Impact factor: 19.103

3.  Hydroxychloroquine retinopathy: is screening necessary?

Authors:  C Blyth; C Lane
Journal:  BMJ       Date:  1998-03-07

4.  A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulphasalazine.

Authors:  I H Nuver-Zwart; P L van Riel; L B van de Putte; F W Gribnau
Journal:  Ann Rheum Dis       Date:  1989-05       Impact factor: 19.103

5.  Normalization of generalized retinal function and progression of maculopathy after cessation of therapy in a case of severe hydroxychloroquine retinopathy with 19 years follow-up.

Authors:  Paul Salu; André Uvijls; Pierre van den Brande; Bart P Leroy
Journal:  Doc Ophthalmol       Date:  2010-04-16       Impact factor: 2.379

Review 6.  Histological and ultrastructural findings in chloroquine-induced cardiomyopathy.

Authors:  C August; H J Holzhausen; A Schmoldt; R Pompecki; S Schröder
Journal:  J Mol Med (Berl)       Date:  1995-02       Impact factor: 4.599

7.  Treatment of lupus syndromes.

Authors:  A J Carmichael
Journal:  BMJ       Date:  1995-07-22

Review 8.  Systemic lupus erythematosus--disease management.

Authors:  M F Gourley
Journal:  Springer Semin Immunopathol       Date:  1994

9.  Retinal toxicity in long term hydroxychloroquine treatment.

Authors:  M Mavrikakis; S Papazoglou; P P Sfikakis; G Vaiopoulos; K Rougas
Journal:  Ann Rheum Dis       Date:  1996-03       Impact factor: 19.103

10.  Chloroquine stimulates nitric oxide synthesis in murine, porcine, and human endothelial cells.

Authors:  D Ghigo; E Aldieri; R Todde; C Costamagna; G Garbarino; G Pescarmona; A Bosia
Journal:  J Clin Invest       Date:  1998-08-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.